Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteoglycans01:05

Proteoglycans

4.2K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.2K
Matrix Proteoglycans and Glycoproteins01:21

Matrix Proteoglycans and Glycoproteins

4.4K
Proteoglycans are extensively glycosylated proteins, commonly found in the extracellular matrix, interwoven with collagen fibers. Hyaline cartilage, the most common type of cartilage in the body, consists of short and dispersed collagen fibers associated with large amounts of proteoglycans. These proteoglycans have long negative charges that attract cations, which in turn attract water molecules. This influx of ions and water molecules swells up the proteoglycan like a water-soaked gel that can...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study.

Lupus science & medicine·2026
Same author

Paired longitudinal tear proteomics reveals persistent ocular surface dysregulation after teprotumumab therapy in thyroid eye disease.

Communications medicine·2026
Same author

Mast cell proteases and their significance in physiology, pathology, and therapeutic approaches.

Pharmacological reviews·2026
Same author

Pericardial fluid extracellular vesicles enhance angiogenesis and blunt cardiac fibrosis in coronary disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

TGFβ-PDL1 signaling in neutrophils preserves lung barrier during hyperinflammation.

Blood·2026
Same author

Decoding the genome of multidrug resistant (MDR) <i>Providencia hangzhouensis</i> from a cerebrospinal fluid infection isolated from the hospital of Kolkata, West Bengal, India.

Microbiology resource announcements·2026

Related Experiment Video

Updated: Nov 4, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Proteoglycan 4 (PRG4) expression and function in dry eye associated inflammation.

Nikhil G Menon1, Ruchi Goyal1, Carolina Lema2

  • 1Biomedical Engineering Department, School of Dental Medicine, UConn Health, Farmington, CT, USA.

Experimental Eye Research
|May 28, 2021
PubMed
Summary

Proteoglycan 4 (PRG4) reduces inflammation and inhibits matrix metalloproteinase-9 (MMP-9) activity in dry eye disease (DED) models. This study shows PRG4’s potential as a therapeutic agent for DED by exploring its anti-inflammatory and protective mechanisms.

Keywords:
Corneal epithelial cellsDry eyeInflammationLubricinPRG4hTCEpi

More Related Videos

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.6K
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
05:21

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

882

Related Experiment Videos

Last Updated: Nov 4, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.6K
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
05:21

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

882

Area of Science:

  • Ophthalmology and Vision Science
  • Immunology
  • Biochemistry

Background:

  • Dry eye disease (DED) affects millions globally, characterized by ocular surface inflammation and matrix metalloproteinase (MMP) activity.
  • Proteoglycan 4 (PRG4), a known lubricant, also exhibits anti-inflammatory properties, suggesting a dual role in ocular health.
  • Recombinant human PRG4 (rhPRG4) has shown promise in improving DED symptoms, necessitating further research into its mechanisms.

Purpose of the Study:

  • To characterize PRG4 expression in human corneal epithelial cells (hTCEpi).
  • To investigate rhPRG4's modulation of inflammatory cytokines and chemokines.
  • To explore rhPRG4 interactions with MMP-9 and its expression in experimental dry eye (EDE) models.

Main Methods:

  • Quantified PRG4 secretion from hTCEpi cells using Western blot and immunocytochemistry.
  • Measured cytokine/chemokine production via ELISA and Luminex; assessed rhPRG4 effects on MMP-9 activity, binding, and expression.
  • Induced EDE in mice to visualize PRG4 expression in corneas and lacrimal glands.

Main Results:

  • hTCEpi cells synthesize and secrete PRG4, with secretion inhibited by TNFα and IL-1β.
  • Exogenous rhPRG4 significantly reduced stimulated chemokine production (IP-10, RANTES, ENA-78, GROα, MIP-3α, MIG) and inhibited MMP-9 activity.
  • EDE decreased PRG4 immunolocalization on the cornea and showed a trend towards reduced PRG4 in lacrimal glands.

Conclusions:

  • rhPRG4 exhibits anti-inflammatory properties by mitigating chemokine production in corneal epithelial cells.
  • rhPRG4 acts as an inhibitor of MMP-9 activity, contributing to ocular surface protection.
  • In vivo PRG4 expression is altered in DED models, supporting its role in the disease and potential as a therapeutic agent.